Studies with ZD1839 in preclinical models
- 28 February 2003
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (1), 12-20
- https://doi.org/10.1053/sonc.2003.50028
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Tyrosine kinase inhibitors—ZD1839 (Iressa)Current Opinion in Oncology, 2001
- Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancerBioorganic & Medicinal Chemistry Letters, 2001
- The Hallmarks of CancerCell, 2000
- Epidermal Growth Factor Protects Epithelial Cells against Fas-induced ApoptosisPublished by Elsevier ,1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Tumor Invasion: Role of Growth Factor-Induced Cell MotilityAdvances in Cancer Research, 1999
- ZD1839, AN EPIDERMAL GROWTH FACTOR TYROSINE KINASE INHIBITOR SELECTED FOR CLINICAL DEVELOPMENTJournal of Immunotherapy, 1997
- Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal AntibodiesJNCI Journal of the National Cancer Institute, 1993
- Expression in rat fibroblasts of a human transforming growth factor-α cDNA results in transformationCell, 1986